Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
Martin Reck(German Center for Lung Research), Stephen V. Liu(Georgetown University), Jong Seok Lee(Brigham and Women's Hospital), Maximilian J. Hochmair(Karl Landsteiner Society), Barzin Y. Nabet(Gene Therapy Laboratory), Gregory J. Gerstner(Illinois CancerCare), Raffaele Califano(The Christie NHS Foundation Trust), Florian Huemer(Chinese University of Hong Kong), Marta Batus(Rush University Medical Center), György Losonczy(Chinese University of Hong Kong), Rafał Dziadziuszko(Gdańsk Medical University), Vaikunth Cuchelkar, Monika Kaul, Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Bradford J. Danner, Shunichi Sugawara(Sendai Kousei Hospital), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Andrea Veatch(Northwest Medical Specialties), Zoran Andric(University Hospital Medical Center Bezanijska kosa), Steven Kao(Chris O’Brien Lifehouse), Huafei Li(Roche (China)), Stefanie Morris(Roche (Switzerland)), Libor Havel(Chinese University of Hong Kong)
Cited by 66
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k